(NASDAQ: TLX) Telix Pharmaceuticals's forecast annual revenue growth rate of 33.27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Telix Pharmaceuticals's revenue in 2025 is $492,583,018.On average, 5 Wall Street analysts forecast TLX's revenue for 2025 to be $271,720,634,086, with the lowest TLX revenue forecast at $265,101,792,120, and the highest TLX revenue forecast at $280,100,796,293. On average, 5 Wall Street analysts forecast TLX's revenue for 2026 to be $333,135,213,145, with the lowest TLX revenue forecast at $292,549,199,890, and the highest TLX revenue forecast at $372,263,835,993.
In 2027, TLX is forecast to generate $389,193,196,271 in revenue, with the lowest revenue forecast at $352,799,607,190 and the highest revenue forecast at $406,690,249,275.